• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Context Therapeutics Inc. - Common Stock (NQ:CNTX)

    0.6009 +0.0509 (+9.25%)
    Streaming Delayed Price Updated: 3:18 PM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,113,379
    Open 0.5700
    Bid (Size) 0.6009 (400)
    Ask (Size) 0.6054 (300)
    Prev. Close 0.5500
    Today's Range 0.5650 - 0.6253
    52wk Range 0.5451 - 3.620
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill

    Performance

    YTD
    -61.2%
    -61.2%
    1 Month
    -78.5%
    -78.5%
    3 Month
    -77.1%
    -77.1%
    6 Month
    -53.8%
    -53.8%
    1 Year
    -8.3%
    -8.3%

    More News

    Read More
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
    From Context Therapeutics Inc.
    Via GlobeNewswire
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Context Therapeutics Reports Full Year 2025 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics to Participate in Upcoming Investor Conferences
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Context Therapeutics Inc.
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics to Participate in Upcoming Investor Conferences
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Context Therapeutics to Participate in Upcoming Investor Conferences
    From Context Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress ↗
    Via Chartmill

    Frequently Asked Questions

    Is Context Therapeutics Inc. - Common Stock publicly traded?
    Yes, Context Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Context Therapeutics Inc. - Common Stock trade on?
    Context Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Context Therapeutics Inc. - Common Stock?
    The ticker symbol for Context Therapeutics Inc. - Common Stock is CNTX on the Nasdaq Stock Market
    What is the current price of Context Therapeutics Inc. - Common Stock?
    The current price of Context Therapeutics Inc. - Common Stock is 0.6009
    When was Context Therapeutics Inc. - Common Stock last traded?
    The last trade of Context Therapeutics Inc. - Common Stock was at 07/01/26 03:18 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.